Published in final edited form as:

Clinic Adv Periodontics. 2011 August 1; 1(2): 88–94. doi:10.1902/cap.2011.110041.

Future Prospects for Periodontal Bioengineering Using Growth Factors

William V. Giannobile^{*,†}, Scott J. Hollister^{†,‡}, and Peter X. Ma^{†,§}

^{*}Department of Periodontics and Oral Medicine and Michigan Center for Oral Health Research, School of Dentistry, University of Michigan, Ann Arbor, MI

[†]Department of Biomedical Engineering, College of Engineering, University of Michigan

[‡]Department of Surgery, School of Medicine, University of Michigan

[§]Department of Biologic and Materials Sciences, School of Dentistry, University of Michigan

Abstract

Polypeptide growth factors have demonstrated strong potential to repair defects associated with teeth and dental implants. Over the past two decades, intense research efforts have led to the clinical development of several growth factors or biologic agents, including bone morphogenetic proteins, platelet-derived growth factor, fibroblast growth factors, and enamel matrix proteins. Several of these growth factors are now being used clinically for a variety of applications, such as the promotion of periodontal regeneration, sinus floor augmentation, and root coverage procedures. Although clinical results have been promising and growth factors add another dimension to clinical care, optimization of growth factor targeting approaches to periodontal wounds remains a challenge. Enhancement of growth factor local application to improve bioavailability, bioactivity, and allowance of three-dimensional reconstruction of complex anatomic defects is a goal. This article will highlight developments for growth factor delivery to better stimulate the wound healing response for periodontal and bone regeneration in the maxillofacial region.

Keywords

Bone morphogenetic proteins; fibroblast growth factors; platelet-derived growth factor; regeneration; regenerative medicine; tissue engineering

Current State-of-the-Art

This special issue highlights the current status of growth factor technologies in the clinical arena. Regenerative medicine and tissue-engineering innovations have greatly advanced periodontology over the past decade.¹ Several key pivotal human clinical trials have led to the clinical application of bone morphogenetic proteins (BMPs) for localized alveolar ridge² and for sinus floor augmentation.³ For platelet-derived growth factor (PDGF), it has been

used for periodontal regeneration^{4,5} and for the promotion of root coverage.⁶ Most recently, fibroblast growth factor-2 (FGF-2) has been evaluated in a large human clinical trial for the promotion of periodontal regeneration.^{7,8} As such, in this issue, Drs. Murakami et al., Misch and Wang, and Kao and Lynch highlight in greater detail not only the specific studies above but other investigations that explore expanded indications of these technologies for application in the clinical arena for oral bone and soft-tissue repair (Table 1). In this perspective, we will highlight several key areas of development that the field is undertaking to better stimulate the wound healing response for periodontal and bone regeneration in the maxillofacial region.

Scaffolding Matrices to Enhance Growth Factor Release to Periodontal and Bone Defects

The use of scaffolding matrices to deliver growth factors to promote periodontal tissue regeneration has been an active area of research.⁹ Controlled release strategies were recently characterized by Hubbell.¹⁰ He specifically characterized controlled release strategies for tissue engineering as 1) bioactive factors mixed with matrices; 2) bioactive factors entrapped within gel matrices; 3) bioactive factors entrapped within hydrophobic microparticles; 4) bioactive factors bound to affinity sites within matrices, and 5) bio-active factors covalently bound to matrices. Of these five categories, only strategies 1, 4, and 5 present the potential for a completely integrated structural delivery because categories 2 and 3 are non-load-bearing vehicles that must be further fixed to a load-bearing structure. However, in the case of periodontal wound repair in space-making defects, the above may be an insignificant limitation. As an example of strategy 2, Lutolf et al.¹¹ used polyethylene glycol-based hydrogels as BMP-2 delivery vehicles in critical sized calvarial defects.

The major class of currently used BMP-2 delivery vehicles fall into category 1, “bioactive factors mixed with matrices.” The best known of these is the current Food and Drug Administration–approved BMP-2 carrier bovine type I collagen sponge¹² that has been used clinically (approved or off-label) for in-spine fusion,^{13–15} tibial nonunion repair,¹⁶ and multiple craniofacial applications, including sinus lift, tooth socket repair, and cleft defects.^{2,3,17} However, collagen sponges are suboptimal delivery devices that often lead to uncontrolled bolus delivery of BMP-2, which allows diffusion of the protein into surrounding soft tissues. The presence of BMP-2 in soft tissues leads to some patient complications, including dysphagia, airway compression in cervical spine fusion, and heterotopic bone formation in the spinal canal.^{18–20}

Alternative materials to collagen sponges have been proposed. Schmidmaier et al.^{21,22} developed bioresorbable poly-(D, L)-lactic acid coatings for BMP-2 delivery in which the BMP-2 was mixed in a thin film of polymer. The release, as with collagen sponges, occurs when the matrix degrades and polymer diffuses from the matrix. They demonstrated significant increases in bone formation but also noted that ≈50% of growth factors using this delivery approach were eluted during the first 48 hours. This fact illustrates the drawback of this (and any) approach mixing biofactors with matrices, namely that once the matrix begins degrading, there is limited control over growth factor diffusion. As such, binding of growth factors directly to biomaterials offers significant potential (see below).

The simplest approach within Hubbell's¹⁰ schema is to bind BMP-2 to natural or enhanced affinity binding sites on complex three-dimensional scaffold surfaces (category 4). This binding often occurs through electrostatic charge interactions between the protein and biomaterial surface. Rai et al.²³ described adsorption of BMP-2 on three-dimensional polycaprolactone (PCL) and PCL/tricalcium phosphate/fibrin composite scaffolds made by fused deposition modeling. They also found that local BMP-2 retention rates on the scaffolds ranged from $\approx 50\%$ to 75% at 2 days, dropping to $\approx 0\%$ to 20% by 15 days.

The last category¹⁰ for controlled release is category 5, "bioactive factors covalently bound to matrices." This method provides the tightest binding of growth factors to substrates and is useful to retain growth factors locally as to avoid dispersion of BMPs into the soft tissues, which can lead to ectopic bone formation.²⁴ To date, there have not been reports related to ectopic bone formation in extraction sockets or in sinus floor elevation procedures.

In the periodontium, the use of these scaffold constructs made of a variety of formulations, such as polymeric bio-materials of polylactic glycolic acid (PLGA), PCL, or polylactic acid, have been well studied.²⁴ These materials have been used extensively to deliver not only growth factors but also genes and cells.²⁵ Additionally, a variety of ceramic biomaterials, such as hydroxyapatite, β -tricalcium phosphate, or other calcium phosphate ceramics, are being used as space-making constructs to support the three-dimensional stability of complex periodontal and peri-implant wound sites. These constructs are being used for growth factor incorporation to provide bolus, pulse, or constant slow release of growth factors. Within the polymeric constructs, microspheres or nanospheres encapsulating growth factors, antibiotics, or other anabolic agents are being used to optimize wound repair and regeneration (Fig. 1).²⁶ More recently, the BMP/transforming growth factor- β family member known to have a role in skeletal and joint development, growth and differentiation factor-5 (GDF-5), has demonstrated significant potential in the regeneration of periodontal ligament (PDL) and bone in vertical bone defects using PLGA and β -tricalcium phosphate carriers.^{27–29} Advances in computer-aided design–computer-aided manufacturer technology over the years coupled with the expanded use of cone beam computed tomography for imaging three-dimensional structures allows for the construction of anatomically corrected scaffolds for intimate, highly accurate fitting to complex topographies of bone^{30–32} and periodontal defects (Fig. 2).³³ Wikesjö et al.³⁴ have demonstrated that BMPs coated onto titanium porous oxide implant surfaces of dental implants allow for the release and subsequent acceleration of osseointegration in alveolar ridge defects.

Emerging Technologies for Gene and Stem Cell Delivery Technologies to Enhance Bioavailability of Growth Factors

The use of gene therapy offers significant potential to target and deliver growth factor genes to periodontal defects.^{35,36} Gene delivery has been shown to increase bioavailability, improve factor targeting to cells within osseous defects, and improve the overall delivery of growth factors to wounds in a more biologically relevant dose level compared to the "dose-dumping" formulations generally used in topical protein delivery of growth factors.³⁷ Growth factors such as PDGF have been used to repair periodontal^{38,39} and peri-implant⁴⁰ bone defects, whereas BMPs have been used to treat a wider range of craniofacial defects,

including the jaws, peri-implant defects,⁴¹ extraction sockets, and periodontal lesions.⁴² The use of gene delivery technologies has shown potential in the clinical arena to stimulate regeneration of chronic diabetic wounds in patients with neuropathic defects.^{43,44} However, at this time, human clinical data are not available for treatment of periodontal defects, only early-stage preclinical safety assessments.³⁸ Early studies for salivary gland repair have demonstrated proof-of-concept in the craniofacial complex.⁴⁵

The use of cell delivery approaches has been reviewed recently for application to oral and periodontal wounds.²⁵ It has been long known that the PDL offers significant regenerative potential as a source of progenitor cells that can regenerate periodontal wounds.^{46,47} The use of stem cell transplantation of PDL progenitors has been demonstrated in vivo in a variety of contexts.^{48,49} Although promising in the administration of cells as local factories to drive production of newly formed tissues, the use of autologous cells for the repair of oral and periodontal wounds is quite limited, primarily from a practical standpoint.⁵⁰ However, the use of allogenic cell-delivery approaches has demonstrated significant potential in several human clinical trials to expand the zone of attached and keratinized gingiva through the production of local growth factors at the wound site.^{51–54} A commercial product has been developed that uses cadaver-derived allogenic stem cells for application in local bone repair procedures.⁵⁵ Recently, cell transplantation of PDL progenitor cells has demonstrated the potential to form hybrid ligament – implant constructs (Fig. 3).^{56,57} As such, there is significant potential for the use of either stem cells or PDL progenitor cells to form both soft and hard periodontal tissues in vivo. However, the practical challenges of regulatory, consistent cell populations from patient-to-patient and time required for procurement will be steps requiring significant optimization before being ready for the clinical arena in a real way.

Perspective

The significant advances in regenerative medicine offers some exciting opportunities for the reconstruction of complex periodontal defects. The field has grown significantly over the past decade, and the use of growth factors for application to periodontal and oral bone wounds is now a clinical reality. The future areas of development remain in delivery strategies to target growth factors to periodontal osseous defects. The use of optimized delivery vehicles will work on controlling the release and improving bioavailability (via improved scaffold designs, three-dimensional customized scaffolds, and possibly gene targeting). The use of stem or progenitor cells to improve cell sourcing to form new tissues and vasculature offers significant potential for robust tissue regeneration. These and other approaches will require important collaborations among biologists, engineers, and periodontal researches in concert with regulatory agencies and leaders to bring these new technologies to the chair-side and clinical practice.

Acknowledgments

This work was supported by National Institutes of Health/National Institute of Dental and Craniofacial Research Grants DE 13397-10 and DE 015384. Drs. Giannobile, Hollister, and Ma hold patents/licenses related to some of the technologies presented in this commentary. Dr. Hollister is the co-founder of a company that makes scaffolds for bone regeneration.

References

1. Zaky SH, Cancedda R. Engineering craniofacial structures: Facing the challenge. *J Dent Res.* 2009; 88:1077–1091. [PubMed: 19897785]
2. Fiorellini JP, Howell TH, Cochran D, et al. Randomized study evaluating recombinant human bone morphogenetic protein-2 for extraction socket augmentation. *J Periodontol.* 2005; 76:605–613. [PubMed: 15857102]
3. Triplett RG, Nevins M, Marx RE, et al. Pivotal, randomized, parallel evaluation of recombinant human bone morphogenetic protein-2/absorbable collagen sponge and autogenous bone graft for maxillary sinus floor augmentation. *J Oral Maxillofac Surg.* 2009; 67:1947–1960. [PubMed: 19686934]
4. Howell TH, Fiorellini JP, Paquette DW, Offenbacher S, Giannobile WV, Lynch SE. A phase I/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in patients with periodontal disease. *J Periodontol.* 1997; 68:1186–1193. [PubMed: 9444594]
5. Nevins M, Giannobile WV, McGuire MK, et al. Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: Results of a large multicenter randomized controlled trial. *J Periodontol.* 2005; 76:2205–2215. [PubMed: 16332231]
6. McGuire MK, Scheyer ET, Schupbach P. Growth factor-mediated treatment of recession defects: A randomized controlled trial and histologic and microcomputed tomography examination. *J Periodontol.* 2009; 80:550–564. [PubMed: 19335074]
7. Kitamura M, Akamatsu M, Machigashira M, et al. FGF-2 stimulates periodontal regeneration: Results of a multi-center randomized clinical trial. *J Dent Res.* 2011; 90:35–40. [PubMed: 21059869]
8. Somerman M. Growth factors and periodontal engineering: Where next? *J Dent Res.* 2011; 90:7–8. [PubMed: 21041551]
9. Owen SC, Shoichet MS. Design of three-dimensional biomimetic scaffolds. *J Biomed Mater Res A.* 2010; 94:1321–1331. [PubMed: 20597126]
10. Hubbell J. Controlled release strategies in tissue engineering. In: van Blitterswijk, C., editor. *Tissue Engineering.* Burlington, VT: Academic Press; 2008. p. 455–482.
11. Lutolf MP, Weber FE, Schmoekel HG, et al. Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. *Nat Biotechnol.* 2003; 21:513–518. [PubMed: 12704396]
12. Geiger M, Li RH, Friess W. Collagen sponges for bone regeneration with rhBMP-2. *Adv Drug Deliv Rev.* 2003; 55:1613–1629. [PubMed: 14623404]
13. Baskin DS, Ryan P, Sonntag V, Westmark R, Widmayer MA. A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONESR allograft ring and the ATLANTIS anterior cervical plate. *Spine.* 2003; 28:1219–1224. discussion 1225. [PubMed: 12811263]
14. Glassman SD, Dimar JR, Carreon LY, Campbell MJ, Puno RM, Johnson JR. Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion. *Spine.* 2005; 30:1694–1698. [PubMed: 16094268]
15. Katayama Y, Matsuyama Y, Yoshihara H, et al. Clinical and radio-graphic outcomes of posterolateral lumbar spine fusion in humans using recombinant human bone morphogenetic protein-2: An average five-year follow-up study. *Int Orthop.* 2009; 33:1061–1067. [PubMed: 18581064]
16. Govender S. The outcome of allografts and anterior instrumentation in spinal tuberculosis. *Clin Orthop Relat Res.* 2002; 398:60–66. [PubMed: 11964632]
17. Dickinson BP, Ashley RK, Wasson KL, et al. Reduced morbidity and improved healing with bone morphogenic protein-2 in older patients with alveolar cleft defects. *Plast Reconstr Surg.* 2008; 121:209–217. [PubMed: 18176223]
18. Boraiah S, Paul O, Hawkes D, Wickham M, Lorch DG. Complications of recombinant human BMP-2 for treating complex tibial plateau fractures: A preliminary report. *Clin Orthop Relat Res.* 2009; 467:3257–3262. [PubMed: 19693635]

19. Traynelis VC. Ectopic bone. *J Neurosurg Spine*. 2010; 12:39. [PubMed: 20043762]
20. Wong DA, Kumar A, Jatana S, Ghiselli G, Wong K. Neurologic impairment from ectopic bone in the lumbar canal: A potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). *Spine J*. 2008; 8:1011–1018. [PubMed: 18037352]
21. Schmidmaier G, Wildemann B, Cromme F, Kandziora F, Haas NP, Raschke M. Bone morphogenetic protein-2 coating of titanium implants increases biomechanical strength and accelerates bone remodeling in fracture treatment: A biomechanical and histological study in rats. *Bone*. 2002; 30:816–822. [PubMed: 12052447]
22. Schmidmaier G, Wildemann B, Stemberger A, Haas NP, Raschke M. Biodegradable poly(D,L-lactide) coating of implants for continuous release of growth factors. *J Biomed Mater Res*. 2001; 58:449–455. [PubMed: 11410904]
23. Rai B, Teoh SH, Ho KH, et al. The effect of rhBMP-2 on canine osteoblasts seeded onto 3D bioactive polycaprolactone scaffolds. *Biomaterials*. 2004; 25:5499–5506. [PubMed: 15142731]
24. Hu J, Ma PX. Nano-fibrous tissue engineering scaffolds capable of growth factor delivery. *Pharm Res*. 2011; 28:1273–1281. [PubMed: 21234657]
25. Rios HF, Lin Z, Oh B, Park CH, Giannobile WV. Cell- and gene-based therapeutic strategies for periodontal regenerative medicine [published online ahead of print February 2, 2011]. *J Periodontol*. 10.1902/jop.2011.100710
26. Ma PX. Scaffolds for tissue fabrication. *Materials Today*. 2004; 7:30–40.
27. Min CK, Wikesjö UM, Park JC, et al. Wound healing/regeneration using recombinant human growth/differentiation factor-5 in an injectable poly-lactide-co-glycolide-acid composite carrier and a one-wall intra-bony defect model in dogs. *J Clin Periodontol*. 2011; 38:261–268. [PubMed: 21219393]
28. Kwon HR, Wikesjö UM, Park JC, et al. Growth/differentiation factor-5 significantly enhances periodontal wound healing/regeneration compared with platelet-derived growth factor-BB in dogs. *J Clin Periodontol*. 2010; 37:739–746. [PubMed: 20618546]
29. Kwon DH, Bennett W, Herberg S, et al. Evaluation of an injectable rhGDF-5/PLGA construct for minimally invasive periodontal regenerative procedures: A histological study in the dog. *J Clin Periodontol*. 2010; 37:390–397. [PubMed: 20447263]
30. Wei G, Ma PX. Partially nanofibrous architecture of 3D tissue engineering scaffolds. *Biomaterials*. 2009; 30:6426–6434. [PubMed: 19699518]
31. Hollister SJ, Levy RA, Chu TM, Halloran JW, Feinberg SE. An image-based approach for designing and manufacturing craniofacial scaffolds. *Int J Oral Maxillofac Surg*. 2000; 29:67–71. [PubMed: 10691148]
32. Hollister SJ. Porous scaffold design for tissue engineering. *Nat Mater*. 2005; 4:518–524. [PubMed: 16003400]
33. Park CH, Rios HF, Jin Q, et al. Biomimetic hybrid scaffolds for engineering human tooth-ligament interfaces. *Biomaterials*. 2010; 31:5945–5952. [PubMed: 20471083]
34. Wikesjö UM, Qahash M, Huang YH, Xiropaidis A, Polimeni G, Susin C. Bone morphogenetic proteins for periodontal and alveolar indications; biological observations – Clinical implications. *Orthod Craniofac Res*. 2009; 12:263–270. [PubMed: 19627529]
35. Ramseier CA, Abramson ZR, Jin Q, Giannobile WV. Gene therapeutics for periodontal regenerative medicine. *Dent Clin North Am*. 2006; 50:245–263. ix. [PubMed: 16530061]
36. Elangovan S, Karimbux N. Review paper: DNA delivery strategies to promote periodontal regeneration. *J Biomater Appl*. 2010; 25:3–18. [PubMed: 20511387]
37. Fischer J, Kolk A, Wolfart S, et al. Future of local bone regeneration: Protein versus gene therapy. *J Craniomaxillofac Surg*. 2011; 39:54–64. [PubMed: 20434921]
38. Chang PC, Cirelli JA, Jin Q, et al. Adenovirus encoding human platelet-derived growth factor-B delivered to alveolar bone defects exhibits safety and biodistribution profiles favorable for clinical use. *Hum Gene Ther*. 2009; 20:486–496. [PubMed: 19199824]
39. Jin Q, Anusaksathien O, Webb SA, Printz MA, Giannobile WV. Engineering of tooth-supporting structures by delivery of PDGF gene therapy vectors. *Mol Ther*. 2004; 9:519–526. [PubMed: 15093182]

40. Chang PC, Seol YJ, Cirelli JA, et al. PDGF-B gene therapy accelerates bone engineering and oral implant osseointegration. *Gene Ther.* 2010; 17:95–104. [PubMed: 19741730]
41. Dunn CA, Jin Q, Taba M Jr, Franceschi RT, Bruce Rutherford R, Giannobile WV. BMP gene delivery for alveolar bone engineering at dental implant defects. *Mol Ther.* 2005; 11:294–299. [PubMed: 15668141]
42. Jin QM, Anusaksathien O, Webb SA, Rutherford RB, Giannobile WV. Gene therapy of bone morphogenetic protein for periodontal tissue engineering. *J Periodontol.* 2003; 74:202–213. [PubMed: 12666709]
43. Blume P, Driver VR, Tallis AJ, et al. Formulated collagen gel accelerates healing rate immediately after application in patients with diabetic neuropathic foot ulcers. *Wound Repair Regen.* 2011; 19:302–308. [PubMed: 21371164]
44. Mulder G, Tallis AJ, Marshall VT, et al. Treatment of non-healing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): Results of a phase 1/2 trial. *Wound Repair Regen.* 2009; 17:772–779. [PubMed: 19821960]
45. Zheng C, Nikolov NP, Alevizos I, et al. Transient detection of E1-containing adenovirus in saliva after the delivery of a first-generation adenoviral vector to human parotid gland. *J Gene Med.* 2010; 12:3–10. [PubMed: 19941317]
46. Fleischmannova J, Matalova E, Sharpe PT, Misek I, Radlanski RJ. Formation of the tooth-bone interface. *J Dent Res.* 2010; 89:108–115. [PubMed: 20042740]
47. Melcher AH. On the repair potential of periodontal tissues. *J Periodontol.* 1976; 47:256–260. [PubMed: 775048]
48. Seo BM, Miura M, Sonoyama W, Coppe C, Stanyon R, Shi S. Recovery of stem cells from cryopreserved periodontal ligament. *J Dent Res.* 2005; 84:907–912. [PubMed: 16183789]
49. Seo BM, Miura M, Gronthos S, et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. *Lancet.* 2004; 364:149–155. [PubMed: 15246727]
50. Kaigler D, Pagni G, Park CH, Tarle SA, Bartel RL, Giannobile WV. Angiogenic and osteogenic potential of bone repair cells for craniofacial regeneration. *Tissue Eng Part A.* 2010; 16:2809–2820. [PubMed: 20412009]
51. McGuire MK, Nunn ME. Evaluation of the safety and efficacy of periodontal applications of a living tissue-engineered human fibroblast-derived dermal substitute. I. Comparison to the gingival autograft: A randomized controlled pilot study. *J Periodontol.* 2005; 76:867–880. [PubMed: 15948680]
52. McGuire MK, Scheyer ET, Nevins M, et al. Living cellular construct for increasing the width of keratinized gingiva. Results from a randomized, within-patient, controlled trial [published online ahead of print March 29, 2011]. *J Periodontol.* 10.1902/jop.2011.100671
53. McGuire MK, Scheyer ET, Nunn ME, Lavin PT. A pilot study to evaluate a tissue-engineered bilayered cell therapy as an alternative to tissue from the palate. *J Periodontol.* 2008; 79:1847–1856. [PubMed: 18834238]
54. Morelli T, Neiva R, Nevins ML, et al. Angiogenic biomarkers and healing of living cellular constructs. *J Dent Res.* 2011; 90:456–462. [PubMed: 21248359]
55. McAllister BS. Stem cell-containing allograft matrix enhances periodontal regeneration: Case presentations. *Int J Periodontics Restorative Dent.* 2011; 31:149–155. [PubMed: 21491014]
56. Gault P, Black A, Romette JL, et al. Tissue-engineered ligament: Implant constructs for tooth replacement. *J Clin Periodontol.* 2010; 37:750–758. [PubMed: 20546087]
57. Giannobile WV. Getting to the root of dental implant tissue engineering. *J Clin Periodontol.* 2010; 37:747–749. [PubMed: 20546086]

FIGURE 1.

Biomimetic nano-scaffold for application in periodontal bioengineering. The scaffold combines novel nano-fibrous architecture of an interconnected pore network with microspheres for controlled release of putative regenerative factors. The nano-fibrous scaffolding design uses the architectural features of collagen, providing a high surface area for cell attachment and new matrix deposition, and an open structure allowing an interactive environment for cell–cell, cell–nutrient, and cell–molecule interactions. The bone mineral mimicking apatite enhances osteoconductivity of the scaffold. The biodegradable microspheres release the regenerative factors in a controlled manner in a targeted local environment. Adapted with permission from Elsevier (reference 26).

FIGURE 2.

The reverse-engineered periodontal defect-fit scaffold modeling and the adaptation of customized designed scaffold on the root surface. **2a** Computer-aided design-based software (NX version 5 software, UGS, Plano, TX) was used to create PDL (red) and bone (blue) interfaces of the hybrid scaffold. The anatomic defect-fit scaffold had the perpendicular-oriented PDL internal channel structures and topological similarities of the periodontal defects. The furcation defect design had separated two different parts with a key (buccal)-lock (lingual) system to make easier assembling and implanting through the buccal-lingual penetration defect region. The red line was the porcine mandible image with the customized scaffold, and the blue line was the exposed periodontal defect site. **2b** The histogram represented the 99.9% adaptable scaffold to the root surface. The measured length was 3.00 mm, and the scaffold was coated by 35% BaSO₄ solution. The yellow lines on the two-dimensionally digitized slices represented the measured regions with 3.00 mm length from the dentin (dental pulp side) to the middle of defect site. AB = alveolar bone; R = tooth root;

Sc = hybrid scaffold. **2c** The histogram was from 83.5% adaptable scaffold image. The concaved region of the red line can represent the gap distance (d^{gap}) between tooth root surface and PDL interface scaffold. **2d** Based on the method in 2c and 2d, total PDL interface length (d^{total}) and d^{gap} were linearly measured, and the adaptation ratio was calculated in each layer, which had three different channel-type structures. There was no statistically significant difference (N.S.) among six different layers, and the range of adaptation was $83.3\% < \text{mean value of adaptation ratio} < 99.0\%$, and data were $\text{mean} \pm \text{SD}$. For the statistical analysis, the non-parametric Kruskal-Wallis one-way analysis of variance test was used. Reproduced with permission from Elsevier (reference 33).

Models for Cell-Based Engineering of Tooth- and Implant-Supporting Tissue Constructs

FIGURE 3. Cell-based therapies for the tissue engineering of teeth, periodontia, and dental implant interfaces. Reprinted with permission from Wiley-Blackwell (reference 57).

TABLE 1

Growth Factors Under Investigation or Approved for Clinical Use

Growth Factor	In Vitro Evidence	Preclinical Evidence	Clinical Evidence
BMP-2	X	X	X
BMP-7	X	X	X
GDF-5	X	X	
FGF-2	X	X	X
PDGF-BB	X	X	X

Preclinical Evidence and Clinical Evidence refer to periodontal applications.